Seaway Pharma Inc. Initiates Class II Recall for Oxymetazoline Hydrochloride Nasal Spray Over CGMP Deviations
Seaway Pharma Inc. has initiated a Class II recall for 7,992 bottles of Oxymetazoline hydrochloride 0.05% nasal spray due to potential microbial contamination in manufacturing water. While final products tested clean, this CGMP deviation highlights critical quality control risks for procurement and regulatory teams. Supply chain VPs should assess exposure in Michigan and Pennsylvania, while business development executives note the ongoing FDA scrutiny on manufacturing processes across the OTC drug sector.
FDA Class II Recall: Seaway Pharma's Oxymetazoline Hydrochloride Nasal Spray
Seaway Pharma Inc., based in Massena, New York, has initiated a voluntary Class II recall, designated D-0216-2024, for 7,992 bottles of its Quality Choice No Drip Extra Moisturizing Nasal Pump Mist Oxymetazoline hydrochloride 0.05%, a 12 Hour Nasal Decongestant. This action, commenced on December 28, 2023, stems from reported Current Good Manufacturing Practice (CGMP) deviations concerning possible microbial contamination in the purified water used during the manufacturing process. For procurement directors, this underscores the critical importance of rigorous supplier qualification and ongoing monitoring of manufacturing environments, even for over-the-counter (OTC) products. While the firm confirmed no contamination was found in the final product, lot # SE23034 with an expiration date of May 31, 2026, the deviation in water quality represents a fundamental breach of CGMP standards. Regulatory affairs heads must recognize that such process failures, even without direct product contamination, can trigger significant regulatory scrutiny and necessitate comprehensive corrective actions. The product, identified by NDC# 63868-676-01 and UPC 6-35515-98847-7, was distributed by C.D.M.A, Inc. to Michigan and Pennsylvania, indicating a localized but impactful supply chain disruption for regional partners. Business development executives should note the potential for brand reputation damage and the need for robust quality assurance frameworks to protect market standing.
Seaway Pharma Inc.'s Operational Profile and Product Focus
Seaway Pharma Inc., operating from 5 County Route 42, Massena, NY 13662-1569, is the recalling firm for the Oxymetazoline hydrochloride 0.05% nasal decongestant. This product falls under the human OTC drug category, a segment characterized by high volume and broad consumer access. The specific molecule, Oxymetazoline hydrochloride, is a well-established alpha-adrenergic agonist used for temporary relief of nasal congestion. For supply chain VPs, understanding a manufacturer's operational focus is crucial; Seaway Pharma's involvement in OTC drug production means that any CGMP deviation can have wide-reaching implications for consumer health and market availability. While specific facility details, capacity, or global API supply roles are not provided in the available intelligence, this recall highlights that even seemingly low-risk products require stringent quality controls. Procurement directors sourcing similar OTC formulations must ensure their partners maintain robust quality management systems, particularly concerning critical utilities like purified water, which is foundational to pharmaceutical manufacturing. The incident serves as a reminder that regulatory compliance is non-negotiable, regardless of product classification, impacting both the direct manufacturer and its distribution partners like C.D.M.A, Inc. (43157 W 9 Mile Rd. Novi, MI 48375).
Supply Chain Exposure: Regional Impact of Oxymetazoline Hydrochloride Recall
The recall of 7,992 bottles of Quality Choice No Drip Extra Moisturizing Nasal Pump Mist Oxymetazoline hydrochloride 0.05% directly impacts distribution channels in Michigan (MI) and Pennsylvania (PA). This targeted distribution pattern means that procurement directors and supply chain VPs with operations or retail presence in these states must immediately assess their inventory levels and potential shortfalls for this specific nasal decongestant. The product, distributed by C.D.M.A, Inc., highlights the interconnectedness of the pharmaceutical supply chain, where a manufacturing issue at one point can ripple through to regional markets. While the total quantity of 7,992 bottles may seem modest in a global context, it represents a complete withdrawal of a specific lot from shelves, potentially causing localized stock-outs or requiring rapid re-sourcing. Business development executives should evaluate their market share and competitive positioning in MI and PA for similar OTC products, as this recall could create temporary market opportunities or expose vulnerabilities in their own supply resilience. Regulatory affairs heads must ensure that their internal recall procedures are robust and that communication with affected distributors and retailers is swift and transparent, mitigating further regulatory risk and maintaining consumer trust in the Oxymetazoline hydrochloride market.
Strategic Sourcing for Oxymetazoline Hydrochloride: Mitigating Supply Risk
Given the Class II recall of Seaway Pharma Inc.'s Oxymetazoline hydrochloride 0.05% nasal spray, procurement directors and supply chain VPs should proactively review their sourcing strategies for this critical OTC molecule. While specific alternative suppliers are not detailed in the available intelligence, the market for Oxymetazoline hydrochloride is generally competitive, with multiple manufacturers globally. The key for decision-makers is to identify and qualify alternative suppliers who demonstrate impeccable CGMP compliance, particularly regarding water systems and environmental controls, to prevent similar quality issues. This involves comprehensive due diligence, including facility audits, review of quality agreements, and assessment of their regulatory history. Geographic diversity in sourcing is also paramount to mitigate risks associated with regional disruptions or single-point-of-failure manufacturing sites. Qualification timelines for new suppliers can range from 6 to 18 months, depending on the complexity of the product and regulatory requirements, emphasizing the need for proactive planning. Business development executives should explore partnerships with manufacturers known for robust quality systems, enhancing product portfolio resilience. Regulatory affairs heads must ensure that any new supplier qualification process adheres strictly to FDA guidelines, minimizing future compliance risks for Oxymetazoline hydrochloride products.
Broader Regulatory Landscape: Persistent CGMP Challenges in Pharma
The Class II recall by Seaway Pharma Inc. for its Oxymetazoline hydrochloride product, driven by CGMP deviations related to purified water, is not an isolated incident but rather indicative of broader, persistent quality control challenges within the pharmaceutical industry. Recent parallel events highlight this trend: Cardinal Health Inc. faced a Class II recall for XIGDUO XR due to storage temperature excursions, Amneal Pharmaceuticals recalled Nizatidine Oral Solution over NDMA contamination and CGMP deviations, and Essential Wellness Pharma's Progesterone Injection failed sterility assurance. These cases, alongside Lupin Pharmaceuticals' Lisinopril Tablets recall due to dose mix-up, underscore a heightened FDA scrutiny on manufacturing processes, quality systems, and supply chain integrity. For regulatory affairs heads, this pattern necessitates a proactive review of all manufacturing and distribution partners to identify and mitigate potential CGMP vulnerabilities before they escalate into recalls or Warning Letters. Supply chain VPs must recognize that quality issues, whether related to water systems, storage conditions, or active pharmaceutical ingredient (API) integrity, pose significant risks to product availability and brand reputation. Business development executives should factor these regulatory trends into their market entry and expansion strategies, prioritizing partners with proven compliance records to navigate an increasingly stringent regulatory environment.
Remediation and Future Compliance Outlook for Seaway Pharma Inc.
The 'ongoing' status of the D-0216-2024 recall for Seaway Pharma Inc.'s Oxymetazoline hydrochloride product signifies that the firm is actively managing the recall process, including retrieving affected units from the market. Beyond this, the core issue of CGMP deviations related to purified water demands a comprehensive remediation strategy. Seaway Pharma Inc. is expected to conduct a thorough root cause analysis to identify why potential microbial contamination occurred in its water system, despite no contamination being found in the final product. This will involve evaluating their water purification, storage, and distribution systems, as well as their environmental monitoring programs. For regulatory affairs heads, this means anticipating potential FDA follow-up inspections to verify the implementation and effectiveness of corrective and preventive actions (CAPA). Failure to adequately address these deviations could lead to further regulatory actions, including potential Warning Letters or even facility shutdowns, impacting future production of Oxymetazoline hydrochloride and other products. Procurement directors and supply chain VPs should monitor Seaway Pharma's progress closely, as sustained compliance is essential for long-term supply stability. Business development executives must understand that a strong commitment to quality and transparent remediation efforts are critical for restoring market confidence and ensuring continued product viability.